FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

Media coverage

• Title	FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression
  Media name/outlet	Hatteras Venture Partners
  Country/Territory	United States
  Date	23/08/23
  URL	https://www.hatterasvp.com/fda-approves-g1-therapeutics-cosela-trilaciclib-the-first-and-only-myeloprotection-therapy-to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression/
  Persons	William Roberts